In the quest for effective gastroenteropancreatic neuroendocrine carcinoma treatments, researchers unleashed patient-derived tumor spheroids. A dazzling 16 compounds, notably tyrosyl-DNA phosphodiesterase 1 inhibitors, emerged as fierce warriors against over 75% of these rare tumors. Cytarabine, a standout from the bunch, synergized with standard drugs, intensifying the battle against cancer cells. These findings spotlight a promising avenue for combating neuroendocrine carcinomas and the potential of innovative drug combinations for improved outcomes.
Journal Article by Beyer GV, Hueser S (…) Ear PH et 5 al. in BMC Surg
Copyright © 2023 Elsevier Inc. All rights reserved.